Glancy Prongay & Murray LLP Commences Investigation on Behalf of Agile Therapeutics, Inc. Investors
Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Agile Therapeutics, Inc.
(“Agile” or the “Company”) (NASDAQ: AGRX) investors concerning the Company and its officers’ possible violations of federal securities laws. GPM is
preparing a lawsuit on behalf of Agile investors.
Agile is a specialty pharmaceutical company that focuses on the development and commercialization of prescription contraceptive
products for women.
On January 3, 2017, Agile disclosed statistical information pertaining to its Phase 3 SECURE study analyzing the Company’s
combined hormonal contraceptive patch Twirla. The study, which was initiated at the request of the FDA, comes after the FDA
rejected Agile's initial marketing application back in 2013. The Company cited "positive top-line results" in the study, yet
reported that almost 2% of subjects experienced "serious adverse events" including "deep vein thrombosis, pulmonary embolism,
gallbladder disease, ectopic pregnancy and depression." Additionally, 51.4% of subjects opted to discontinue the study.
On this news, Agile stock fell nearly 64% during intraday trading on January 4, 2017.
If you purchased Agile securities, have information or would like to learn more about these claims, or have any questions
concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at
310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and
number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Glancy Prongay & Murray LLP, Los Angeles/New York
Lesley Portnoy, 310-201-9150 or 888-773-9224
shareholders@glancylaw.com
www.glancylaw.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20170105006248/en/